Halichondrin Analog Synthesis via C38 Ketal Equilibration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing halichondrin A and its analogs are complex and lack efficient synthetic routes, hindering the development of new anti-proliferative agents with improved efficacy and safety for treating proliferative diseases like cancer.
Innovation Solution
The synthesis of halichondrin A and its analogs, including norhalichondrin A and homohalichondrin A, through acid-mediated equilibration at the C38 ketal stereocenter, along with methods for interconverting these compounds and preparing pharmaceutical compositions for treating proliferative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current synthesis methods are used for halichondrin A and its analogs, then the structural complexity and diversity of halichondrin series compounds can be achieved, but the synthetic process becomes excessively complex and inefficient
Solution Approach 1:
The synthesis is divided into modular segments: (1) preparation of spiroketal intermediates with defined stereocenters, (2) acid-mediated equilibration at C38 to establish the ketal stereocenter, and (3) coupling reactions to assemble the complete halichondrin backbone. This segmentation allows each module to be optimized independently while maintaining overall structural diversity.
Solution Approach 2:
The patent employs parameter changes in the form of acid-mediated equilibration conditions to transform the C38 ketal stereocenter. By controlling acid concentration, temperature, and reaction time, the method efficiently establishes the correct stereochemistry without requiring complex chiral catalysts or multiple protection/deprotection steps, thereby simplifying the synthetic route while maintaining adaptability to produce various halichondrin analogs.
2Adaptability or versatility
If complex synthesis routes are employed to produce halichondrin analogs, then diverse structures can be obtained, but the productivity and availability of these anti-proliferative agents are reduced
Solution Approach 1:
The methodology performs preliminary action by pre-establishing the C38 ketal stereocenter through acid-mediated equilibration before final coupling steps. This advance preparation of the stereocenter eliminates the need for subsequent chiral resolution or complex stereoselective reactions, thereby streamlining the synthesis and improving productivity without limiting the diversity of final analogs that can be produced.
Solution Approach 2:
The patent uses spiroketal intermediates as mediating structures that facilitate the assembly of halichondrin analogs. These intermediates contain pre-formed stereocenters and reactive functionality that enable efficient coupling to diverse side chains, thereby maintaining analog diversity while reducing the overall number of synthetic steps required and improving production efficiency.
3Reliability
If traditional synthesis methods are used, then halichondrin compounds can be produced, but the synthetic route lacks efficiency and hinders development of new anti-proliferative agents
Solution Approach 1:
The acid-mediated equilibration process exhibits self-service characteristics where the reaction conditions automatically favor formation of the thermodynamically stable C38 ketal stereocenter configuration. The system self-regulates to produce the correct stereochemistry without requiring external chiral influence or multiple purification steps, thereby maintaining reliable production of halichondrin compounds while significantly improving synthetic efficiency and facilitating rapid development of new anti-proliferative agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of halichondrin A and its analogs, providing effective anti-proliferative agents for cancer treatment by simplifying the synthetic process and enhancing the availability of these compounds for clinical use.
Implementation Method 1
methods for interconverting between the halichondrins, norhalichondrins, and homohalichondrins, and their unnatural epimers at the C38 ketal stereocenter through the use of an acid-mediated equilibration
Data Source
AI summary
The present invention provides halichondrin analogs, such as compounds of Formula (I). The compounds may bind to microtubule sites, thereby inhibiting microtubule dynamics. Also provided are methods of synthesis, pharmaceutical compositions, kits, methods of treatment, and uses that involve the compounds for treatment of a proliferative disease (e.g., cancer). Compounds of the present invention are particularly useful for the treatment of metastatic breast cancer, non-small cell lung cancer, prostate cancer, and sarcoma. The included methods of synthesis are useful for the preparation of compounds of Formula (I)-(III) along with naturally occurring halicondrins (e.g., halichondrin B & C, norhalichondrin A, B, & C, and homohalichondrin A, B, & C). Also included are methods for interconverting between the halichondrins, norhalichondrins, and homohalichondrins and their unnatural epimers at the C38 ketal stereocenter through the use of an acid-mediated equilibration.